Introduction
In 1995 1 the investigators of the United Kingdom Prospective Diabetes Study (UKPDS) published the results of 6 years of therapy with a variety of blood glucose-lowering drugs in patients with 2DM. Although the major goal of the study was to evaluate the relationship between glycaemic control and the development of diabetic complications, the report contained metabolic data which have had a substantial impact on general views as to the pathophysiology of 2DM. Specifically, using HOMA-beta, a surrogate estimate of pancreatic beta-cell function based on measurements of fasting plasma glucose and insulin concentrations, 2 it was concluded that approximately 50% of insulin secretory capacity had been lost in these patients prior to initiation of the study. Following enrolment, there was a progressive deterioration of glycaemic control over the next 6 years in all groups, including those assigned to 'intensive' glycaemic intervention. beta-cell function as estimated by HOMA-beta also decreased continuously over the study period, leading the authors to conclude that 'progressively increasing hyperglycaemia, associated with decreasing beta-cell function, was a marked feature irrespective of the therapy used. ' HOMA-beta has continued to be used as an estimate of beta-cell function in the years following the publication of the UKPDS report, with essentially similar conclusions as to the progressive loss of insulin secretory function over the natural history of 2DM. For example, HOMA-beta was used in the recent study 3 A Diabetes Outcome Progression Trial (ADOPT) to assess changes in beta-cell function over time in patients with 2DM assigned to monotherapy with rosiglitazone, metformin or glyburide. The major conclusion of ADOPT was that although the three drugs differed in length of time for monotherapy to fail, the data were consistent with the UKPDS results in that the initial improvement in glycaemic control was followed by a progressive increase in glycated haemoglobin and fasting plasma glucose concentration. The effect of treatment on the estimate of beta-cell function was somewhat more complicated than reported by the UKPDS, consisting of an initial improvement following initiation of drug treatment, but after this 'levels of beta-cell function declined in all three groups.'
The notion of a progressive and inexorable loss of beta-cell function as part of the natural history of 2DM has been buttressed by results suggesting that in order to attain glycaemic control in patients with 2DM over time additional pharmacological agents must continually be added. This point was initially made in one of the reports of the UKPDS, 4 but is echoed in the findings of the ADOPT study. The remainder of this analysis will be devoted to consideration of the appropriateness of HOMA-beta as an assessment of insulin secretory function, as well as the notion that glycaemic control inexorably declines with duration of 2DM.
HOMA-beta as an Estimate of Insulin Secretory Function
HOMA-beta is based upon measurement of FPG and FPI concentrations. 2 The formula can be written in more than one way, but this is a practical version:
HOMA-beta=FPI concentration (μU/ml) × 20/FPG (mmol/L)-3.5.
Given its formulation, it should not be surprising that degree of hyperglycaemia is a crucial determinant of the magnitude of HOMA-beta. For example, a person with NGT and a FPG of 4.4 mmol/L would have a denominator in the HOMA-beta formula of 0.9 (4.4 mmol/L-3.5). In contrast, a patient with 2DM and a FPG concentration of 12.5 mmol/L would have a denominator of 9.0 (12.5 mmol/L-3.5).
If it is assumed that the subject with NGT has a FPI of10 μU/ml (a not unreasonable value), HOMA-beta in this individual would be as follows: 20 x 10/0.9=222. If the patient with 2DM had a FPI twice that of the person with NGT (20 μU/ml), HOMA-beta in the patient with diabetes would be 20 x 20/9.0=44; markedly reduced. Indeed, in order to have the same value for HOMA-beta as the individual with NGT, the patient with 2DM would have to have a FPI concentration of 100 μU/ml: 20 x 100/9.0=222.
Given the calculations outlined above, and in light of abundant information that FPI concentration in patients with 2DM are only mildly elevated, at best, when compared with subjects with NGT, there is no doubt that HOMA-beta will decrease progressively as FPG concentration increases. Thus, despite having a doubling of FPI concentration, as in the example described above, the patient with 2DM would still be considered to be 'insulin deficient' on the basis of the HOMA-beta calculation indicating that pancreatic beta-cell function was only approximately 20% of the value in the person with NGT.
The conclusion that a patient whose FPI concentration is twice as high as another is insulin deficient depends upon the assumption that the plasma insulin concentration should be a direct function of the coexisting plasma glucose concentration; the higher the FPG concentration, the higher in proportion must be the FPI concentration, or else the beta cell has failed. On the other hand, could it not be argued that if the FPI in the patient with 2DM is twice as high in patients with NGT, the FPG should not be so high. Stated more explicitly, why is it physiologically correct to consider the plasma insulin concentration in light of the plasma glucose concentration, rather than view the plasma glucose concentration in terms of the insulin concentration? The obvious answer to this rhetorical question is that in order for the HOMA-beta to provide a reliable estimate of insulin secretory function the relationship between plasma glucose and insulin concentrations 'must' be considered in light of the assumption that the coexisting plasma glucose concentration is the sole modulator of the plasma insulin concentration. The appropriateness of this premise will be viewed in the next section.
Relationship between Coexisting Plasma Glucose and Insulin Concentrations
As indicated above, the validity of HOMA-beta as a measure of insulin secretory function depends to a large extent on the assumption that the primary determinant of the insulin secretory response is the coexisting plasma glucose concentration. Even if the level of glycaemia plays the dominant role in modulation of pancreatic beta-cell function after an overnight fast, it need not be the case in the post-prandial state. Indeed, there are at least three other physiological variables that affect the amount of insulin that is secreted in response to a glucose challenge. Perhaps the most obvious example of the dissociation between the coexisting plasma glucose and insulin concentrations is seen when consideration is given to the route by which the glucose is administered. Thus, as summarised by Dupre, 5 'the delivery of glucose into the intestine is followed by the development of higher blood levels of immunoreactive insulin or insulin-like activity than those attained when similar levels of blood glucose are produced by the intravenous infusion of glucose'.
Secondly, although conveniently ignored, the load of administered glucose is an important regulator of insulin secretion. For example, simply doubling the amount of oral glucose given to healthy medical students from (20 g/m² to 40 g/m²) does not result in any significant difference in the subsequent glucose excursions. 6 On the other hand, plasma insulin concentrations are much higher in those given the greater amount of glucose, despite the similarity in the coexisting plasma glucose concentrations. These data further demonstrate that there is no unique relationship between coexisting plasma glucose and insulin concentrations, and it will vary significantly as a function of the amount of glucose given.
Finally, variations in the ability of insulin to simulate glucose disposal will change the relationship between coexisting plasma glucose concentration and insulin concentrations. The data in figure 1 depict plasma glucose and insulin responses to a 75 g oral glucose load in 100 apparently healthy individuals, divided into quartiles on the basis of their degree of insulin sensitivity as quantified by the hyperinsulinaemic, euglycaemic clamp technique: quartile 1 the most insulin resistant, quartile 4 the most insulin sensitive. 7 It can be seen that the plasma glucose concentrations in the four groups are comparable at every time point, whereas plasma insulin concentrations increase progressively as a function of degree of insulin resistance.
A more sophisticated demonstration of the impact of differences in insulin sensitivity on the relationship between coexisting plasma glucose and insulin concentrations can be found in the results of Jones et al. 8 These authors used the graded glucose infusion introduced by Polonsky et al. 9 to compare GS-IS rates in NGT individuals, divided into insulin resistant IR and IS subgroups. FPG (4.7 vs. 4.4 mmol/L) and FPI (12 vs. 9 μU/ml) concentrations were somewhat higher in the IR group, and, as shown below, HOMA-beta values were similar in the two groups: IS=20 × 9/4.4-3.5=180/0.9=200, IR=20 × 12/4.7-3.5=240/1.2=200.
However, despite the similarity of insulin secretory function as quantified by HOMA-beta, when the GS-IS rates were compared it was obvious that the insulin secretion rate was significantly increased (p<0.001) at every molar increment in plasma glucose concentration in the IR group. In other words, there was a significant shift to the left in the insulin secretory dose response curve in the IR individuals; they secreted more insulin at every given increment in plasma glucose concentration than did the IS subjects.
Based on the experimental data reviewed in this section it seems obvious that the coexisting glucose concentration is only one of the physiological variables that modulate the insulin secretory response, and that HOMA-beta values do not necessarily prove an adequate measure of pancreatic beta-cell function.
HOMA-beta versus Insulin Response to Mixed Meals
FPI concentrations vary modestly as fasting hyperglycaemia develops. Consequently, it is obvious that HOMA-beta concentrations will be lower in patients with progressive degrees of fasting hyperglycaemia. However, when measurements are made of day-long insulin concentrations in response to mixed meals a quite different view emerges of the relationship between insulin secretion and increases in level of glycaemia. For example, figure 2 displays day-long plasma and glucose concentrations in response to mixed meals in nonobese and obese individuals with NGT, IGT or 2DM. 10 The HOMA-beta values of the three nonobese groups are calculated below: NGT=20 × 10 (FPI)/4.4 (FPG) -3.5= 200/0.9=222, IGT=20 × 16 (FPI)/5.8 (FPG) -3.5= 320/2.3=139, 2DM=20 × 13 FPI)/12.5 (FPG) -3.5=260/9.0=29.
It can be seen that the HOMA-beta value of nonobese patients with 2DM was markedly reduced as compared with values of subjects with NGT and IGT, respectively, and comparable relationships obtained in the three diagnostic groups of obese individuals. If HOMA-beta is used to assess insulin secretory function, the conclusion from this study would be that it was reduced in patients with 2DM to ~15% of the value of subjects with NGT. In contrast, it is apparent from figure 2 that day-long plasma insulin concentrations in response to mixed meals in absolute terms were, if anything, higher in the patients with 2DM than in those with NGT. Obviously, the level of compensatory hyperinsulinaemia in those with 2DM was not sufficient to prevent hyperglycaemia, but these patients had day-long plasma insulin concentrations that were intermediate between those of the NGT and IGT groups. Perhaps the most dramatic difference between estimates of insulin secretory function is seen in the comparison of the NGT and IGT groups. HOMA-beta values were approximately twice as high in those with NGT, whereas day-long plasma insulin concentrations were almost twice as high in those with IGT.
Another example of how conclusions concerning insulin secretory function in patients with 2DM can vary so dramatically as a function of how it is quantified is apparent from results of studies in which plasma glucose and insulin concentrations were measured at hourly intervals over a 24-hour period in response to mixed meals at 8 a.m., 12 p.m., and 6 p.m. 11 These measurements were made in three groups of subjects: NGT; 2DM with mean FPG concentrations ≤175 mg/dL; and 2DM with FPG ≥250 mg/dL. Since FPI concentrations were comparable in the three groups, both at times zero and 24 h, whereas FPG concentrations were quite different, insulin secretory function as assessed by HOMA-IR decreased progressively with degree of fasting hyperglycaemia. However, when hourly insulin responses were compared, plasma insulin concentrations were significantly higher than in those with a FPG concentration <175 mg/dL, as compared with NGT individuals, and there was no significant difference between the hourly plasma insulin concentrations in the normal group and those with 2DM and FPG >175 mg/dL.
The implications of the studies described above are two-fold. At the simplest level, these results suggest that use of HOMA-beta as the sole assessment of insulin secretory function may not provide a totally accurate view of the absolute ability of the pancreatic beta cell to secrete insulin. In addition, they highlight a somewhat paradoxical, and poorly understood, phenomenon concerning the relationship between hyperglycaemia and insulin secretory function. As emphasised above, FPI concentrations in patients with 2DM, and significant elevations of FPG concentration, are similar, or slightly higher, than FPI concentrations in those with NGT. However, when they eat mixed meals, as illustrated in figure 2, they are able to significantly increase their insulin secretory response. Consequently, it seems necessary to ask why, if they are capable of secreting additional amounts of insulin in response to meals, they do not secrete more insulin in the fasting state in order to lower their FPG concentration? Speculation as to the physiological explanation for this apparent dichotomous behaviour of the pancreatic beta cell in the fasting versus the post-prandial state is not appropriate within the context of this analysis, but it raises another reason why simply measuring HOMA-beta might not provide a definitive evaluation of insulin secretory function.
How Inexorable is the Loss of Insulin Secretory Function as Hyperglycaemia Progresses in Patients with 2DM?
As discussed above, there seems to be a general consensus that the natural history of 2DM is characterised by a progressive loss of insulin secretory function, and this process is viewed as an inexorable characteristic of the clinical syndrome. [1] [2] [3] [4] Although considerable support for this belief is based upon estimates of beta-cell function that can be questioned for reasons outlined above, its acceptance has been buttressed by studies suggesting that it in order to attain glycaemic control in patients with 2DM over time additional forms of therapy must continuously be added. 3, 4 In contrast to this point of view, there is evidence that there is not an inexorable loss of insulin secretory function in patients with 2DM, and that maintenance of glycaemic control need not depend upon the continued addition of new pharmacological agents. As regards the first point, Andrews et al. 12 aggressively administered insulin for 4 weeks to 13 Pima Indians with hyperglycaemia (133 to 303 mg/dL), some with a duration of 2DM of 12 years, and assessed the effect of this intervention on insulin secretory function. The results clearly indicated that the patients in this study had not suffered an inexorable loss of beta-cell function. For example, in response to an oral glucose challenge 'both the early (0-30 min) and total integrated insulin responses above fasting increased 2.5-fold after therapy) P<0.05 and <0.001, respectively).' It should also be noted that the improvement in the insulin response to oral glucose persisted for at least two weeks following insulin withdrawal, and did not seem to vary as a function of duration of diabetes.
As concerns the second point, there are at least two studies in which patients with 2DM, presumably failing monotherapy with a glucose-lowering drug, were restored to significantly better glycaemic control without adding a second pharmacological agent; in both instances, simply by losing a relatively modest amount of weight. Thus, Liu et al. 13 indicated that weight loss of an average of 6.4 kg in10 patients with 2DM, classified as 'sulphonylurea failures', was associated with a 46% decline in fasting plasma glucose concentration, falling from a mean of 281 mg/dL to 152 mg/dL. Obviously, this substantial improvement in glycaemia occurred in the absence of adding another pharmacological agent.
An even more dramatic example of why the simple fact of monotherapy failure does not necessarily imply the progressive loss of beta-cell function is found in the report of our research group of the benefits of weight loss in 12 older patients (71±2 years of age), whose fasting glucose concentration was 258±0 mg/dL on an average insulin dose of 52±5 units/day. 14 Following an average weight loss of 9 kg, these same patients were in much better glycaemic control, with a fasting plasma glucose concentration of 137±4 mg/ dL while receiving monotherapy with a SU compound.
Closer examination of the results of the ADOPT study 3 raise additional questions concerning the ability of HOMAbeta to provide accurate pathophysiological insight into the changes in insulin secretory function that occur over time in patients with 2DM, as well as the notion that an inexorable loss of beta-cell function is a characteristic feature of this syndrome. Perhaps this analysis can be best accomplished by dividing the study into two parts: the initial improvement in glycaemic control and the period in which control deteriorated.
During the first 6 months after initiation of treatment glycaemic control improved and HOMA-beta increased in response to all three drugs. Both of these changes were most striking in the glyburide-treated individuals, presumably because SU compounds are known to be insulin secretagogues. However, the impact of SU compounds on FPI concentrations is minimal, at best, and it has been shown that after a few months of treatment with these agents the insulin response to glucose is, if anything, the same or lower than before the drug was administered. 15, 16 Consequently, it is difficult to attribute the improvement in glycaemic control documented 6 months after starting glyburide to a persistent elevation of circulating insulin concentration. Instead it seems more likely that the dramatic increase in HOMA-beta value 6 months after the drug was started in glyburide-treated patients is a straightforward mathematical consequence of the greater decrease in FPG in the absence of any change in FPI.
The relationship between improvement in glucose control and associated changes in HOMA-beta seen in the first 6 months following metformin and rosiglitazone administration is also of interest. The fall in FPG and glycated haemoglobin concentrations was less than that seen in glyburide-treated patients, as was the increase in HOMA-beta. However, since neither fasting nor day-long plasma insulin concentrations increase when either metformin or rosiglitazone are used to improve glycaemic control in patients with 2DM, 17, 18 it seems unlikely that an increase in insulin secretion was responsible for the fall in FPG and glycated haemoglobin concentration seen in these individuals, despite the associated increase in HOMA-beta. Rather, the increase in HOMA-beta most likely occurred because both these drugs improved glycaemic control, without any increase in insulin secretion, emphasising the predominant role that a fall in FPG plays in the calculation of HOMA-beta.
Turning now to the period in which glycaemic control is progressively deteriorating in all three treatment groups, the results in ADOPT demonstrate that this is occurring in association with a progressive decline in insulin secretion as estimated by measurement of HOMAbeta. The deterioration of glycaemic control and decrease in HOMA-beta was greatest in the glyburide-treated patients, intermediate in those receiving metformin, and least in the patients treated with rosiglitazone. Without more information it is not clear how best to interpret these data. The authors conclude that the slower rate of decline in glycaemic control in the rosiglitazone-treated group was due to better maintenance of insulin secretory function as measured by HOMA-beta, whereas it was the more rapid loss of beta-cell function that led to the accentuated increase in FPG and glycated haemoglobin concentrations in those receiving glyburide. However, could it not be simply that rosiglitazone was more effective than glyburide in maintaining glycaemic control, with the lower FPG concentrations in these patients being responsible for the difference in HOMA-beta values? Consistent with this notion is the fact that the estimates of insulin sensitivity indicated that it increased significantly during treatment with rosiglitazone, with little change in those treated with glyburide.
Conclusion
In this analysis data has been reviewed that questions the use of HOMA-beta to arrive at the apparent consensus that the natural history of 2DM is characterised by a continuous decline in insulin secretory function, and that this putative progressive loss of beta-cell function is also inexorable. The thrust of the review clearly questions this conventional wisdom, but in so doing provides each reader with the opportunity to address this question themselves. How persuasive the challenge to clinical dogma that has resulted from this analysis can be debated, but the physiological and clinical implications that result if the natural history of 2DM is not characterised by an inexorable, progressive, and absolute loss of insulin secretory function is self-evident. It certainly seems worthy of further discussion, and even more so of experimental evaluation.
